Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025

Reuters

Aug 02

Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025

Exicure Inc. has announced the completion of the last patient, last visit in its Phase 2 clinical trial evaluating the safety and efficacy of GPC-100 (burixafor) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplant. The study, which is assessing the ability of GPC-100, a CXCR4 antagonist, to enhance CD34+ hematopoietic stem cell mobilization, is being conducted in combination with propranolol and G-CSF. Topline results from this randomized, open-label, multicenter study are expected in the fourth quarter of 2025. The company is also exploring the use of GPC-100 in other therapeutic areas, including a planned Phase 1 study in acute myeloid leukemia patients and potential collaborations for its application in cell and gene therapy settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250801325070) on August 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2556504845"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556504845\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556504845?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-02 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556504845","market":"fut","top_or_hot":-1,"title":"Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Exicure Inc. has announced the completion of the last patient, last visit in its Phase 2 clinical trial evaluating the safety and efficacy of GPC-100 (burixafor) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplant. The study, which is assessing the ability of GPC-100, a CXCR4 antagonist, to enhance CD34+ hematopoietic stem cell mobilization, is being conducted in combination with propranolol and G-CSF. Topline results from this randomized, open-label, multicenter study are expected in the fourth quarter of 2025. The company is also exploring the use of GPC-100 in other therapeutic areas, including a planned Phase 1 study in acute myeloid leukemia patients and potential collaborations for its application in cell and gene therapy settings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250801325070) on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-02 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Exicure Inc. has announced the completion of the last patient, last visit in its Phase 2 clinical trial evaluating the safety and efficacy of GPC-100 (burixafor) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplant. The study, which is assessing the ability of GPC-100, a CXCR4 antagonist, to enhance CD34+ hematopoietic stem cell mobilization, is being conducted in combination with propranolol and G-CSF. Topline results from this randomized, open-label, multicenter study are expected in the fourth quarter of 2025. The company is also exploring the use of GPC-100 in other therapeutic areas, including a planned Phase 1 study in acute myeloid leukemia patients and potential collaborations for its application in cell and gene therapy settings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250801325070) on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL2G4Nyg:1","article_id":"2556504845","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556504845","pubTimestamp":1754078473,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via Business Wire  on August 01, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XCUR":"Exicure, Inc."},"translate_title":"Exicure Inc.完成GPC-100增强多发性骨髓瘤患者干细胞动员的2期研究，预计2025年底取得主要结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XCUR":0.9},"content_text":"Exicure Inc. Completes Phase 2 Study of GPC-100 for Enhanced Stem Cell Mobilization in Multiple Myeloma Patients, Topline Results Expected in Late 2025\n    \n\n        Exicure Inc. has announced the completion of the last patient, last visit in its Phase 2 clinical trial evaluating the safety and efficacy of GPC-100 (burixafor) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplant. The study, which is assessing the ability of GPC-100, a CXCR4 antagonist, to enhance CD34+ hematopoietic stem cell mobilization, is being conducted in combination with propranolol and G-CSF. Topline results from this randomized, open-label, multicenter study are expected in the fourth quarter of 2025. The company is also exploring the use of GPC-100 in other therapeutic areas, including a planned Phase 1 study in acute myeloid leukemia patients and potential collaborations for its application in cell and gene therapy settings.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250801325070) on August 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}